Global GLP-1 Diabetes Treatment Drugs Market Growth 2025-2031
Description
The global GLP-1 Diabetes Treatment Drugs market size is predicted to grow from US$ 6472 million in 2025 to US$ 26200 million in 2031; it is expected to grow at a CAGR of 26.2% from 2025 to 2031.
The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.
GLP-1 is a core drug used to treat type 2 diabetes by mimicking the effects of the body's natural hormone GLP-1. It regulates blood sugar mainly by activating GLP-1 receptors to enhance insulin secretion, reduce glucagon release, delay gastric emptying and suppress appetite. Some types are also approved for obesity management.
United States market for GLP-1 Diabetes Treatment Drugs is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for GLP-1 Diabetes Treatment Drugs is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for GLP-1 Diabetes Treatment Drugs is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key GLP-1 Diabetes Treatment Drugs players cover Eli Lilly, Sanofi, Novo Nordisk, Hanmi Pharmaceutical Co, Boehringer Ingelheim, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
LP Information, Inc. (LPI) ' newest research report, the “GLP-1 Diabetes Treatment Drugs Industry Forecast” looks at past sales and reviews total world GLP-1 Diabetes Treatment Drugs sales in 2024, providing a comprehensive analysis by region and market sector of projected GLP-1 Diabetes Treatment Drugs sales for 2025 through 2031. With GLP-1 Diabetes Treatment Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world GLP-1 Diabetes Treatment Drugs industry.
This Insight Report provides a comprehensive analysis of the global GLP-1 Diabetes Treatment Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on GLP-1 Diabetes Treatment Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global GLP-1 Diabetes Treatment Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for GLP-1 Diabetes Treatment Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global GLP-1 Diabetes Treatment Drugs.
This report presents a comprehensive overview, market shares, and growth opportunities of GLP-1 Diabetes Treatment Drugs market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Laglutide
Dulaglutide
Exenatide
Others
Segmentation by Application:
Online Pharmacy
Hospital
Clinic
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Eli Lilly
Sanofi
Novo Nordisk
Hanmi Pharmaceutical Co
Boehringer Ingelheim
AstraZeneca
Pfizer Inc
Teva Pharmaceutical Industries Ltd
GlaxoSmithKline (GSK)
Ganli Pharmaceuticals
Tonghua Dongbao
Shanghai Renhui Biopharmaceuticals Co., Ltd.
Huadong Medicine
Page Biopharmaceuticals
Jiangsu Hausen Pharmaceuticals Group Co., Ltd.
Key Questions Addressed in this Report
What is the 10-year outlook for the global GLP-1 Diabetes Treatment Drugs market?
What factors are driving GLP-1 Diabetes Treatment Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do GLP-1 Diabetes Treatment Drugs market opportunities vary by end market size?
How does GLP-1 Diabetes Treatment Drugs break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.
GLP-1 is a core drug used to treat type 2 diabetes by mimicking the effects of the body's natural hormone GLP-1. It regulates blood sugar mainly by activating GLP-1 receptors to enhance insulin secretion, reduce glucagon release, delay gastric emptying and suppress appetite. Some types are also approved for obesity management.
United States market for GLP-1 Diabetes Treatment Drugs is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for GLP-1 Diabetes Treatment Drugs is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for GLP-1 Diabetes Treatment Drugs is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key GLP-1 Diabetes Treatment Drugs players cover Eli Lilly, Sanofi, Novo Nordisk, Hanmi Pharmaceutical Co, Boehringer Ingelheim, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
LP Information, Inc. (LPI) ' newest research report, the “GLP-1 Diabetes Treatment Drugs Industry Forecast” looks at past sales and reviews total world GLP-1 Diabetes Treatment Drugs sales in 2024, providing a comprehensive analysis by region and market sector of projected GLP-1 Diabetes Treatment Drugs sales for 2025 through 2031. With GLP-1 Diabetes Treatment Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world GLP-1 Diabetes Treatment Drugs industry.
This Insight Report provides a comprehensive analysis of the global GLP-1 Diabetes Treatment Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on GLP-1 Diabetes Treatment Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global GLP-1 Diabetes Treatment Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for GLP-1 Diabetes Treatment Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global GLP-1 Diabetes Treatment Drugs.
This report presents a comprehensive overview, market shares, and growth opportunities of GLP-1 Diabetes Treatment Drugs market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Laglutide
Dulaglutide
Exenatide
Others
Segmentation by Application:
Online Pharmacy
Hospital
Clinic
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Eli Lilly
Sanofi
Novo Nordisk
Hanmi Pharmaceutical Co
Boehringer Ingelheim
AstraZeneca
Pfizer Inc
Teva Pharmaceutical Industries Ltd
GlaxoSmithKline (GSK)
Ganli Pharmaceuticals
Tonghua Dongbao
Shanghai Renhui Biopharmaceuticals Co., Ltd.
Huadong Medicine
Page Biopharmaceuticals
Jiangsu Hausen Pharmaceuticals Group Co., Ltd.
Key Questions Addressed in this Report
What is the 10-year outlook for the global GLP-1 Diabetes Treatment Drugs market?
What factors are driving GLP-1 Diabetes Treatment Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do GLP-1 Diabetes Treatment Drugs market opportunities vary by end market size?
How does GLP-1 Diabetes Treatment Drugs break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
118 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 2 Executive Summary
- 3 Global by Company
- 4 World Historic Review for GLP-1 Diabetes Treatment Drugs by Geographic Region
- 5 Americas
- 6 APAC
- 7 Europe
- 8 Middle East & Africa
- 9 Market Drivers, Challenges and Trends
- 10 Manufacturing Cost Structure Analysis
- 11 Marketing, Distributors and Customer
- 12 World Forecast Review for GLP-1 Diabetes Treatment Drugs by Geographic Region
- 13 Key Players Analysis
- 14 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
